Lisinopril is a an angiotensin-converting enzyme (ACE) inhibitor and used to treat hypertension, heart failure, and heart attacks. For high blood pressure it is usually a first-line treatment. Lisinopril is also used to prevent kidney problems in people with diabetes mellitus. The drug ranks as the third most prescribed drug in the U.S., with 82.5 million prescriptions in 2022. Developed by Merck and approved in 1987.

Nurtec® ODT, developed by Biohaven and acquired by Pfizer for $11.6 billion in 2022 (via Pfizer’s acquisition of Biohaven), is a calcitonin gene-related peptide (CGRP) receptor antagonist. Approved for acute treatment and prevention of episodic migraines in adults in 2020. Pfizer reported revenue of US$928 million for Nurtec ODT/Vydura in 2023.

Xiidra, developed by Shire (later acquired by Takeda) and purchased by Novartis for $3.4 billion in 2019 (Novartis-Takeda deal), is a prescription eye drop approved in 2016 for treating signs and symptoms of dry eye disease in adults (FDA approval announcement). Containing lifitegrast, it targets inflammation by inhibiting T-cell activity, offering relief from dryness and discomfort, often within weeks. Novartis sold it to Bausch + Lomb in 2023 for $1.75 billion, reflecting its $487 million 2022 sales.

Zejula, developed by Tesaro and acquired by GSK for $5.1 billion in 2019 (GSK-Tesaro acquisition), is a PARP inhibitor approved in 2017 for maintenance treatment of recurrent ovarian, fallopian tube, or peritoneal cancer in adults (FDA approval announcement). It targets DNA repair pathways to delay cancer progression and is also approved for first-line maintenance in platinum-responsive advanced ovarian cancer.